Rachel Jamison Perry, PhD
Research & Publications
Biography
News
Locations
Research Summary
The Perry lab aims to determine how systemic metabolism intersects with immunometabolism to alter outcomes in cancer, sepsis, and other pathologic conditions.
Extensive Research Description
I am an Assistant Professor in Cellular & Molecular Physiology and Internal Medicine (Endocrinology) focusing on tumor metabolism as well as on the impact of systemic metabolism on the response to inflammatory, carcinogenic, and other insults. My training focused on the development and application of stable isotope tracer methodologies to measure hepatic oxidative flux rates, and to use these methods to examine (1) the mechanism by which hyperglycemia develops in poorly-controlled type 1 and type 2 diabetes, and potential therapeutic approaches to treat it, (2) the mechanism by which glycemia is defended during starvation, (3) the mechanism by which inflammation and alterations in the gut microbiota contribute to the pathogenesis of obesity and insulin resistance, and (4) the development of novel mitochondrial uncouplers to treat non-alcoholic fatty liver disease, liver fibrosis, type 2 diabetes, and liver cirrhosis.
My young laboratory draws upon my training in the mechanisms of maintenance of glycemia and in the development of stable isotope tracer methods to model these effects, to examine the mechanism by which obesity drives the development and progression of multiple tumor types. We have shown that insulin drives glucose uptake and oxidation, resulting in increased tumor growth in vivo and in vitro in obesity-associated tumor types, in a result that appears to translate to humans, and that insulin-lowering approaches (mitochondrial uncoupling, SGLT2 inhibition) slow colon and breast cancer growth by reversing hyperinsulinemia-induced increases in tumor glucose uptake and oxidation. Current work in our laboratory expands these analyses to understand the impact of metabolic dysfunction on substrate utilization in addition tumor types, both associated and unassociated with obesity, and in the interplay between immune cells and tumor cells. Both in the lab and in the greater Yale community, I have a strong commitment to teaching and mentoring. I currently mentor two high school students, an undergraduate, five Ph.D. students, and an Associate Research Scientist, and am the co-lead instructor of a graduate-level class in metabolism. As a mentor and a member of two graduate admissions committees, I am also deeply committed to achieving a diverse and equitable training environment within Yale and in the greater scientific community, and actively seek to promote those values throughout my work.
Coauthors
Research Interests
Hyperglycemia; Hyperinsulinism; Insulin Resistance; Magnetic Resonance Spectroscopy
Selected Publications
- A precision medicine approach to metabolic therapy for breast cancer in miceAkingbesote ND, Norman A, Zhu W, Halberstam AA, Zhang X, Foldi J, Lustberg MB, Perry RJ. A precision medicine approach to metabolic therapy for breast cancer in mice Communications Biology 2022, 5: 478. PMID: 35595952, PMCID: PMC9122928, DOI: 10.1038/s42003-022-03422-9.
- Gene and protein expression and metabolic flux analysis reveals metabolic scaling in liver ex vivo and in vivoAkingbesote N, Leitner B, Jovin D, Desrouleaux R, Owusu D, Zhu W, Li Z, Pollak M, Perry R. Gene and protein expression and metabolic flux analysis reveals metabolic scaling in liver ex vivo and in vivo ELife 2023, 12: e78335. PMID: 37219930, PMCID: PMC10205083, DOI: 10.7554/elife.78335.
- Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunityZhang X, Halberstam A, Zhu W, Leitner B, Thakral D, Bosenberg M, Perry R. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity Cancer & Metabolism 2022, 10: 21. PMID: 36457136, PMCID: PMC9714036, DOI: 10.1186/s40170-022-00296-7.
- Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma.Zhang X, Lee WD, Leitner BP, Zhu W, Fosam A, Li Z, Gaspar RC, Halberstam AA, Robles B, Rabinowitz JD, Perry RJ. Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma. Am J Physiol Endocrinol Metab 2023 PMID: 37646579, DOI: 10.1152/ajpendo.00105.2023.
- Tissue-specific reprogramming of glutamine metabolism maintains tolerance to sepsisLeitner B, Lee W, Zhu W, Zhang X, Gaspar R, Li Z, Rabinowitz J, Perry R. Tissue-specific reprogramming of glutamine metabolism maintains tolerance to sepsis PLOS ONE 2023, 18: e0286525. PMID: 37410734, PMCID: PMC10325078, DOI: 10.1371/journal.pone.0286525.
- A review of the impact of energy balance on triple-negative breast cancer.Akingbesote N, Owusu D, Liu R, Cartmel B, Ferrucci L, Zupa M, Lustberg M, Sanft T, Blenman K, Irwin M, Perry R. A review of the impact of energy balance on triple-negative breast cancer. JNCI Monographs 2023, 2023: 104-124. PMID: 37139977, DOI: 10.1093/jncimonographs/lgad011.
- The impact of variance in carnitine palmitoyltransferase-1 expression on breast cancer prognosis is stratified by clinical and anthropometric factorsLiu R, Ospanova S, Perry R. The impact of variance in carnitine palmitoyltransferase-1 expression on breast cancer prognosis is stratified by clinical and anthropometric factors PLOS ONE 2023, 18: e0281252. PMID: 36735704, PMCID: PMC9897541, DOI: 10.1371/journal.pone.0281252.
- Insulin and cancer: a tangled webLeitner BP, Siebel S, Akingbesote ND, Zhang X, Perry RJ. Insulin and cancer: a tangled web Biochemical Journal 2022, 479: 583-607. PMID: 35244142, PMCID: PMC9022985, DOI: 10.1042/bcj20210134.
- An optimized method for tissue glycogen quantificationSchaubroeck KJ, Leitner BP, Perry RJ. An optimized method for tissue glycogen quantification Physiological Reports 2022, 10: e15195. PMID: 35179318, PMCID: PMC8855679, DOI: 10.14814/phy2.15195.
- Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinomaLeitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma Npj Precision Oncology 2022, 6: 8. PMID: 35087143, PMCID: PMC8795406, DOI: 10.1038/s41698-021-00248-2.
- 1713-P: Adipocyte O-GlcNAc Transferase Regulate Adipogenesis through De Novo Lipogenesis in MiceMORINO K, TSUJI A, OHASHI N, IDA S, PERRY R, UGI S, FUJITA Y, SHULMAN G, MAEGAWA H. 1713-P: Adipocyte O-GlcNAc Transferase Regulate Adipogenesis through De Novo Lipogenesis in Mice Diabetes 2020, 69 DOI: 10.2337/db20-1713-p.
- Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysisPerry RJ, Zhang D, Guerra MT, Brill AL, Goedeke L, Nasiri AR, Rabin-Court A, Wang Y, Peng L, Dufour S, Zhang Y, Zhang XM, Butrico GM, Toussaint K, Nozaki Y, Cline GW, Petersen KF, Nathanson MH, Ehrlich BE, Shulman GI. Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis Nature 2020, 579: 279-283. PMID: 32132708, PMCID: PMC7101062, DOI: 10.1038/s41586-020-2074-6.
- The Impact of Obesity on Tumor Glucose Uptake in Breast and Lung CancerLeitner BP, Perry RJ. The Impact of Obesity on Tumor Glucose Uptake in Breast and Lung Cancer JNCI Cancer Spectrum 2020, 4: pkaa007. PMID: 32368718, PMCID: PMC7190208, DOI: 10.1093/jncics/pkaa007.
- SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemiaNasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia Cancer & Metabolism 2019, 7: 10. PMID: 31867105, PMCID: PMC6907191, DOI: 10.1186/s40170-019-0203-1.
- Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidationRabin-Court A, Rodrigues MR, Zhang XM, Perry RJ. Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation PLOS ONE 2019, 14: e0218126. PMID: 31188872, PMCID: PMC6561592, DOI: 10.1371/journal.pone.0218126.
- Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon CancerWang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer Cell Reports 2018, 24: 47-55. PMID: 29972790, PMCID: PMC6056247, DOI: 10.1016/j.celrep.2018.06.008.
- THU-450 Mechanism for hypertriglyceridemia and effect of fibrate coadministration during acetyl-CoA carboxylase inhibitor treatmentGoedeke L, Bates J, Vatner D, Perry R, Ellis M, Wang T, Subramanian M, Myers R, Ray A, Shulman G. THU-450 Mechanism for hypertriglyceridemia and effect of fibrate coadministration during acetyl-CoA carboxylase inhibitor treatment Journal Of Hepatology 2018, 68: s333. DOI: 10.1016/s0168-8278(18)30885-7.
- Leptin Mediates a Glucose-Fatty Acid Cycle to Maintain Glucose Homeostasis in StarvationPerry RJ, Wang Y, Cline GW, Rabin-Court A, Song JD, Dufour S, Zhang XM, Petersen KF, Shulman GI. Leptin Mediates a Glucose-Fatty Acid Cycle to Maintain Glucose Homeostasis in Starvation Cell 2018, 172: 234-248.e17. PMID: 29307489, PMCID: PMC5766366, DOI: 10.1016/j.cell.2017.12.001.
- Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanismsFerrandino G, Kaspari RR, Spadaro O, Reyna-Neyra A, Perry RJ, Cardone R, Kibbey RG, Shulman GI, Dixit VD, Carrasco N. Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: e9172-e9180. PMID: 29073114, PMCID: PMC5664516, DOI: 10.1073/pnas.1707797114.
- Non-invasive assessment of hepatic mitochondrial metabolism by positional isotopomer NMR tracer analysis (PINTA)Perry RJ, Peng L, Cline GW, Butrico GM, Wang Y, Zhang XM, Rothman DL, Petersen KF, Shulman GI. Non-invasive assessment of hepatic mitochondrial metabolism by positional isotopomer NMR tracer analysis (PINTA) Nature Communications 2017, 8: 798. PMID: 28986525, PMCID: PMC5630596, DOI: 10.1038/s41467-017-01143-w.
- Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndromePerry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, Petersen KF, Kibbey RG, Goodman AL, Shulman GI. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome Nature 2016, 534: 213-217. PMID: 27279214, PMCID: PMC4922538, DOI: 10.1038/nature18309.
- Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in ratsPerry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats Science 2015, 347: 1253-1256. PMID: 25721504, PMCID: PMC4495920, DOI: 10.1126/science.aaa0672.
- Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 DiabetesPerry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, Jurczak MJ, Abudukadier A, Han MS, Zhang XM, Ruan HB, Yang X, Caprio S, Kaech SM, Sul HS, Birnbaum MJ, Davis RJ, Cline GW, Petersen KF, Shulman GI. Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes Cell 2015, 160: 745-758. PMID: 25662011, PMCID: PMC4498261, DOI: 10.1016/j.cell.2015.01.012.